HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer

被引：0

作者：

Sawada, Kentaro ^{[1
]}

Kawamoto, Yasuyuki ^{[2
]}

Yuki, Satoshi ^{[3
]}

Nakamura, Michio ^{[4
]}

Muto, Osamu ^{[5
]}

Sogabe, Susumu ^{[6
]}

Shindo, Ysohiaki ^{[7
]}

Ishiguro, Atsushi ^{[8
]}

Sato, Atsushi ^{[9
]}

Tsuji, Yasushi ^{[10
]}

Dazai, Masayoshi ^{[11
]}

Okuda, Hiroyuki ^{[12
]}

Sasaki, Takahide ^{[13
]}

Harada, Kazuaki ^{[2
]}

Nakano, Shintaro ^{[2
]}

Nakatsumi, Hiroshi ^{[3
]}

Sekiguchi, Mari ^{[14
]}

Sakata, Yuh ^{[15
]}

Sakamoto, Naoya ^{[3
]}

Komatsu, Yoshito ^{[2
]}

机构：

[1] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan

[2] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan

[6] KKR Sapporo Med Ctr, Dept Med Oncol, Sapporo, Hokkaido, Japan

[7] Nakadori Gen Hosp, Dept Surg, Akita, Japan

[8] Teine Keijinkai Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[9] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[10] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[11] Sapporo Med Ctr NTT EC, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[12] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[13] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[14] Hokkaido Gastrointestinal Canc Study Grp, Data Ctr, Sapporo, Hokkaido, Japan

[15] Misawa City Hosp, Misawa, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO26-5

引用

页码：S314 / S314

页数：1

共 50 条

[1] Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
Kawamoto, Yasuyuki
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Sasaki, Takahide
Harada, Kazuaki
Nakano, Shintaro
Nakatsumi, Hiroshi
Sekiguchi, Mari
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[2] Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer
Nakamura, M.
Kawamoto, Y.
Yuki, S.
Sawada, K.
Muto, O.
Sogabe, S.
Shindo, Y.
Ishiguro, A.
Sato, A.
Tsuji, Y.
Dazai, M.
Okuda, H.
Sasaki, T.
Harada, K.
Nakatsumi, H.
Iuchi, K.
Sakata, Y.
Komatsu, Y.
ANNALS OF ONCOLOGY, 2021, 32 : S131 - S131
[3] Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Kawamoto, Yasuyuki
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Meguro, Takashi
Harada, Kazuaki
Sekiguchi, Mari
Okada, Kazufumi
Ito, Yoichi M.
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
ONCOLOGIST, 2022, 27 (08): : E642 - E649
[4] Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Sawada, Kentaro
Kawamoto, Yasuyuki
Harada, Kazuaki
Ando, Takayuki
Sogabe, Susumu
Kobayashi, Yoshimitsu
Dazai, Masayoshi
Nakamura, Michio
Hatanaka, Kazuteru
Ishiguro, Atsushi
Sato, Atsushi
Nakano, Shintaro
Shindo, Yoshiaki
Hosokawa, Ayumu
Ito, Ken
Yoshikawa, Ayumu
Iuchi, Kayoko
Yokota, Isao
Yuki, Satoshi
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 447 - 447
[5] HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second -line treatment in patients with metastatic or advanced gastric cancer.
Ishiguro, Atsushi
Kawamoto, Yasuyuki
Yuki, Satoshi
Kobayashi, Yoshimitsu
Harada, Kazuaki
Sogabe, Susumu
Tsuji, Yasushi
Nakano, Shintaro
Sawada, Kentaro
Muranaka, Tetsuhito
Nakatsumi, Hiroshi
Dazai, Masayoshi
Sasaki, Takahide
Eto, Kazunori
Nakamura, Michio
Muto, Osamu
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[6] Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
Saito, Rika
Kawamoto, Yasuyuki
Yuki, Satoshi
Sogabe, Susumu
Dazai, Masayoshi
Hosokawa, Ayumu
Sawada, Kentaro
Sato, Atsushi
Nakamura, Michio
Hatanaka, Kazuteru
Ishiguro, Atsushi
Muto, Osamu
Shindo, Yoshiaki
Tsuji, Yasushi
Tateyama, Miki
Ueda, Akira
Sasaki, Takahide
Katagiri, Masaki
Sakamoto, Naoya
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
Schlintl, Verena
Huemer, Florian
Greil, Richard
Weiss, Lukas
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 906 - 909
[8] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Taroh Satoh
Kyung Hee Lee
Sun Young Rha
Yasutsuna Sasaki
Se Hoon Park
Yoshito Komatsu
Hirofumi Yasui
Tae-You Kim
Kensei Yamaguchi
Nozomu Fuse
Yasuhide Yamada
Takashi Ura
Si-Young Kim
Masaki Munakata
Soh Saitoh
Kazuto Nishio
Satoshi Morita
Eriko Yamamoto
Qingwei Zhang
Jung-mi Kim
Yeul Hong Kim
Yuh Sakata
Gastric Cancer, 2015, 18 : 824 - 832
[9] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Satoh, Taroh
Lee, Kyung Hee
Rha, Sun Young
Sasaki, Yasutsuna
Park, Se Hoon
Komatsu, Yoshito
Yasui, Hirofumi
Kim, Tae-You
Yamaguchi, Kensei
Fuse, Nozomu
Yamada, Yasuhide
Ura, Takashi
Kim, Si-Young
Munakata, Masaki
Saitoh, Soh
Nishio, Kazuto
Morita, Satoshi
Yamamoto, Eriko
Zhang, Qingwei
Kim, Jung-mi
Kim, Yeul Hong
Sakata, Yuh
GASTRIC CANCER, 2015, 18 (04) : 824 - 832
[10] Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer
Nature Reviews Gastroenterology & Hepatology, 2014, 11 (11) : 642 - 642

← 1 2 3 4 5 →